Related by context. All words. (Click for frequent words.) 73 statistically significant 66 clinically meaningful differences 64 statistically significant correlation 63 statistically significant improvement 62 statistically significant correlations 61 statistically significant reduction 61 nonsignificant 60 P = .# 60 achieved statistical significance 59 tertile 59 Subgroup analyzes 59 Baseline characteristics 59 TEAEs 59 inverse association 58 reach statistical significance 58 clinically meaningful improvement 58 Univariate analysis 57 univariate analysis 57 multivariate analyzes 57 discontinuations due 57 multivariable analysis 57 statistical significance 57 laboratory abnormalities 57 clinically meaningful 57 endometrial thickness 57 discontinuations 57 covariate 56 nondiabetic patients 56 SGRQ 56 placebo 56 p = 56 multivariate analysis 55 highest tertile 55 secondary endpoints 55 nonfatal MI 55 quartiles 55 clinically meaningful improvements 55 Kaplan Meier analysis 55 HbA 1c 55 Multivariate analysis 55 univariate 55 progression TTP 55 fasting insulin 55 intima media thickness 54 thromboembolic events 54 hsCRP levels 54 prespecified 54 correlation 54 posttreatment 54 multivariate Cox 54 multivariate adjustment 54 ipsilateral stroke 54 n = 54 tumor histology 54 hypoglycemic events 54 LVEF 54 statistically significant p 54 NYHA functional class 54 secondary efficacy endpoints 54 lowest tertile 54 nonobese 54 oxycodone CR 54 BMI z 54 probable stent thrombosis 54 Multivariate analyzes 54 tapentadol ER 54 achieve statistical significance 54 noninferiority 54 randomized 53 DAS# scores 53 p = #.# [002] 53 p = .# [002] 53 serum concentrations 53 virologic response 53 Secondary endpoints included 53 postintervention 53 secondary endpoint 53 preoperative PSA 53 Secondary endpoints include 53 intact parathyroid hormone 53 tertiles 53 intraobserver 53 ± SD 53 demonstrated statistically significant 53 virologic failure 53 pCR 53 subgroup analyzes 53 histologic 53 prospectively defined 53 Secondary endpoints 53 BMI waist circumference 53 lumbar spine BMD 53 elevated ALT 53 estimated glomerular filtration 53 confidence interval CI 53 hydroxyvitamin D concentrations 53 potential confounders 53 cardiovascular mortality 53 multivariate logistic regression 53 ADAS cog 53 pharmacokinetic interaction 53 % CI #.#-#.# [007] 53 insulin glargine 53 dose limiting toxicities 53 bivariate analyzes 53 biochemical recurrence 53 nonrandomized 53 glycated hemoglobin HbA1c 52 subthreshold depression 52 #mg/day [001] 52 carotid intima media 52 covariates 52 CC genotype 52 placebo fluoxetine 52 WOMAC scores 52 FOLPI 52 tHcy 52 VADT 52 definite stent thrombosis 52 interobserver reliability 52 limiting toxicity 52 plasma cortisol 52 HBeAg negative patients 52 HbA1C levels 52 WOMAC pain 52 ANOVA 52 -#.# ± [002] 52 MetS 52 desvenlafaxine succinate 52 systolic BP 52 morphometric vertebral fractures 52 evaluable 52 NLX P# 52 clinically relevant 52 paclitaxel eluting stents 52 sirolimus eluting stents 52 highest quintile 52 placebo p 52 transaminase elevations 52 statistically significant p = 52 DAS# remission 52 cytogenetic response 52 HOMA IR 52 logistic regression analyzes 52 logistic regression model 52 HAM D# 52 HRQoL 52 QRS duration 52 CVD mortality 52 MMSE score 51 differentially expressed 51 Subgroup analysis 51 nonsignificant trend 51 #mg BID [001] 51 p = NS 51 % CI #.#-#.# [002] 51 intraclass correlation coefficients 51 mg kg dose 51 subanalysis 51 prespecified secondary 51 DLTs 51 advanced adenomas 51 plasma leptin 51 regression analyzes 51 ≥ 51 depressive symptoms 51 IPSS 51 Cmax 51 locoregional recurrence 51 attain statistical significance 51 nadroparin 51 subscale scores 51 SNP rs# [002] 51 noninferior 51 MMSE scores 51 sociodemographic variables 51 placebo p = 51 stent binary restenosis 51 tiotropium 51 unfractionated heparin 51 myocardial infarctions 51 troponin T 51 μmol L 51 Psoriasis Area 51 logistic regression models 51 comorbidities 51 % CI #.#-#.# [006] 51 inflammatory biomarkers 51 VcMP 51 MACCE 51 nodal metastases 51 statistically nonsignificant 51 corrected QT interval 51 intima media thickness IMT 51 CR nPR 51 lispro 51 multivariable Cox 51 undetectable HBV DNA 51 logistic regression analysis 51 Rating Scale MADRS 51 virologic responses 51 QoL 51 median PFS 51 Kaplan Meier curves 51 symptom severity 51 seroprotection 51 colorectal adenoma 51 TIMP 1 51 binary restenosis 51 APTIVUS r 51 elevated creatinine 51 #mg BID [002] 51 MADRS score 51 mcg QD 50 symptomatic VTE 50 primary endpoint 50 prognostic factors 50 tirofiban 50 Univariate 50 ± SEM 50 Secondary efficacy endpoints 50 UPDRS motor 50 ADAS Cog 50 alanine aminotransferase 50 insulin detemir 50 PSQI 50 QTcF 50 timepoint 50 locomotor activity 50 Score TOS 50 postoperative chemotherapy 50 rs# [004] 50 macrovascular disease 50 serum IGF 50 randomized controlled trials 50 endoscopic remission 50 β blockers 50 AUC0 50 mg QD 50 HNSCC 50 strongest predictor 50 hematologic toxicity 50 femoral neck BMD 50 -#.# log# copies mL 50 multivariable adjustment 50 lowest quintile 50 HER2 expression 50 lymph node involvement 50 CIMZIA TM certolizumab pegol 50 secondary efficacy endpoint 50 Unified Parkinson Disease 50 % Confidence Interval 50 NHANES III 50 parous women 50 primary efficacy endpoint 50 plasma lipids 50 Primary endpoints 50 sd = 50 REYATAZ r arm 50 eplerenone 50 substudy 50 confidence intervals CIs 50 antipsychotic efficacy 50 NNRTI resistance 50 #mg BID [003] 50 Rating Scale UPDRS 50 QTc prolongation 50 chlorthalidone 50 HbA1c levels 50 adalimumab 50 dose Iluvien 50 CI -#.# 50 mg ustekinumab 50 Stent thrombosis 50 rCBF 50 genotypic resistance 50 SCr 50 Adverse events 50 strongest predictors 50 androgen suppression 50 achieved ACR# 50 cerebrovascular events 50 concomitant medications 50 hip BMD 50 tipranavir r 50 median survivals 50 recurrent venous thromboembolism 50 nausea photophobia 50 coronary stenosis 50 plasma selenium 50 plasma pharmacokinetics 50 PASI scores 50 methacholine challenge 50 lanthanum carbonate 50 serum parathyroid hormone 50 FOLFOX4 50 perioperative complications 50 lactate dehydrogenase 50 serum triglycerides 50 confidence interval #.#-#.# 50 PCWP 50 abacavir lamivudine 50 prospectively stratified 50 interquartile range 50 distant metastases 50 atazanavir ritonavir 50 nonresponders 50 venlafaxine XR 50 depressive symptom 50 comparator arm 50 QTc 50 NIHSS 50 serum vitamin D 50 lopinavir r arm 50 certolizumab 50 coronary artery calcification 50 systolic blood pressures 50 TT genotype 50 RCTs 50 QTc interval 50 microbleeds 49 CCyR 49 leucopenia 49 dose proportionality 49 serum leptin 49 ibandronate 49 euthyroid 49 Main Outcome Measures 49 glycosylated hemoglobin HbA1c 49 EQ 5D 49 HbA 1c levels 49 patients evaluable 49 postoperatively 49 WOMAC 49 LV dysfunction 49 interrater reliability 49 ipsilateral 49 #mg QD [001] 49 % CI #.#-#.# [003] 49 bivariate analysis 49 adiponectin concentrations 49 convergent validity 49 demonstrated clinically meaningful 49 NYHA class 49 nonsignificant difference 49 events SAEs 49 systolic 49 oral glucose tolerance 49 prospective cohort 49 randomized trials 49 decrements 49 serum estradiol 49 interobserver 49 composite endpoint 49 histologic subtype 49 non inferiority 49 APOE genotype 49 ATACAND 49 abdominal circumference 49 Montgomery Åsberg Depression 49 non squamous histology 49 subclinical hypothyroidism 49 elevated LDH 49 sustained virological response 49 Free Survival PFS 49 fasting plasma glucose 49 YMRS 49 recurrent ischemia 49 randomized #:#:# 49 confounders 49 colorectal adenomas 49 bivariate 49 Visual Analogue Scale VAS 49 severe hypoglycemia 49 HDRS 49 6MWD 49 plus MTX 49 mRS 49 multivariable logistic regression 49 events AEs 49 fosamprenavir 49 familial clustering 49 abciximab 49 preintervention 49 TDF FTC 49 carotid stenosis 49 beta carotene supplementation 49 tumor shrinkage 49 serum bilirubin 49 adenoma recurrence 49 heavily pretreated 49 doxorubicin docetaxel 49 metabolic parameters 49 SHBG levels 49 albumin excretion rate 49 airway responsiveness 49 conditional logistic regression 49 TIMI 49 serum markers 49 baseline HbA1c 49 actigraphy 49 neurologic progression 49 ECOG 49 osteopenic 49 CI #.#-#.# [002] 49 dapagliflozin plus 49 efficacy endpoints 49 fasting glucose levels 49 postop 49 hemoglobin A1c HbA1c 49 neoadjuvant 49 ticagrelor 49 elevated transaminases 49 elevated troponin 49 1mg dose 49 caspofungin 49 nonmetastatic 49 subclinical hyperthyroidism 49 pegylated liposomal doxorubicin 49 coronary calcification 49 LAB GHRH 49 Brief Psychiatric 49 anthropometric measures 49 ADCS CGIC 49 correlation coefficients 49 r = 49 ug dose 49 pT3 49 DAS# CRP 49 lipid parameters 49 diuretic chlorthalidone 49 Apgar scores 49 serum lipids 49 vertebral fracture 49 serum selenium 49 apolipoprotein B 49 UPDRS 49 stent thromboses 49 #mg/kg [002] 49 clinico pathological 49 creatinine ratio 49 apnea hypopnea index 49 #mg QD [002] 49 TAXUS Stent 49 correlational 49 periprocedural MI 49 posttransplant 49 Median survival 49 p = #.# [004] 49 NIHSS score 49 avosentan 49 hemoglobin A1c levels 49 mcg Albuferon 49 everolimus eluting stents 49 ABC/3TC 49 nonexposed 48 serum retinol 48 active comparator 48 adverse perinatal 48 Montgomery Asberg Depression 48 fondaparinux 48 nicardipine 48 rs# [001] 48 ANCOVA 48 platelet reactivity 48 retrospective cohort 48 baseline FEV 48 Kaplan Meier survival 48 oral prednisolone 48 annualized relapse 48 comorbidity 48 HRQOL 48 postoperative complications 48 psychosocial variables 48 mcg albinterferon alfa 2b 48 #.#mg/dL 48 pulmonary exacerbations 48 correlated inversely 48 cardiovascular calcification 48 multivariable analyzes 48 pressor response 48 serum PSA 48 Plasma concentrations 48 sirolimus eluting stent 48 echocardiographic 48 impaired fasting glucose 48 sleeve lobectomy 48 normotensive 48 prednisone prednisolone plus 48 clinically meaningful reductions 48 pentoxifylline 48 confounding factors 48 extrapyramidal symptoms 48 prostate cancer CaP 48 docetaxel pretreated 48 biochemical relapse 48 CT urography 48 QTc intervals 48 androgen deprivation 48 intraocular inflammation 48 abatacept 48 depressive symptomatology 48 divalproex 48 creatinine levels 48 postoperative complication 48 seropositivity 48 left ventricular dysfunction 48 montelukast 48 glycated hemoglobin 48 anemia hemoglobin 48 HAM D 48 sociodemographic factors 48 VT VF 48 LEXIVA r 48 umol L 48 nonfatal stroke 48 PREZISTA r arm 48 interobserver agreement 48 5-FU/LV 48 clinicopathological 48 posttest 48 sirolimus stent 48 certolizumab pegol 48 tamsulosin 48 serum phosphorus 48 carotid plaque 48 p = .# [001] 48 Kaplan Meier curve 48 treatment emergent adverse 48 haematologic 48 symptom exacerbation 48 meta regression 48 aspartate aminotransferase 48 periprocedural 48 arterial occlusion 48 enthesitis 48 Alzheimer Disease Assessment 48 systolic blood pressure 48 dichotomized 48 urodynamic parameters 48 plasma lipid 48 F FDG PET 48 arterial thromboembolic events 48 OADs 48 urinary N telopeptide 48 glycosylated hemoglobin 48 deep venous thromboses 48 serum cotinine 48 unfractionated heparin UFH 48 chlorambucil 48 Pharmacokinetic 48 cystatin C 48 lipid lowering drugs 48 headache nasopharyngitis 48 cytogenetic abnormalities 48 multiple logistic regression 48 pretransplant 48 viral kinetic 48 macrovascular 48 cerebral oxygenation 48 timepoints 48 odds ratios ORs 48 correlations 48 relapsers 48 ALT elevations 48 selenium supplementation 48 PREZISTA r 48 AST ALT 48 oral diclofenac 48 Logistic regression 48 glycated hemoglobin levels 48 serum IgE 48 primary efficacy endpoints 48 extracapsular extension 48 mild renal insufficiency 48 proportional hazards 48 habitual snoring 48 nondiabetic 48 p = #.# [003] 48 Pred Forte 48 elevated hsCRP 48 creatine supplementation 48 ADCS ADL 48 Torsades de Pointes 48 asthma exacerbation 48 splenectomized patients 48 inversely associated 48 solifenacin 48 LPV r 48 diastolic blood pressures 48 virological response 48 postmenopausal osteoporotic women 48 DAS# [002] 48 histological subtype 48 severe exacerbations 48 subscales 48 interindividual variability 48 univariate analyzes 48 subtrochanteric 48 noncardiac 48 dietary calcium intake 48 aminotransferases 48 ropivacaine 48 achieving PASI 48 allele frequencies 48 HF hospitalization 48 systolic dysfunction 48 randomisation 48 Doxil ® 48 HSCT 48 CORE OM 48 Hb A1C 48 noncarriers 48 multivariable adjusted 48 comorbid conditions 48 Events MACE 48 SSRI citalopram 48 Score DAS# 48 Logistic regression analyzes 48 serum folate 48 XIENCE V demonstrated 48 QRS interval 48 #q# deletion syndrome 48 mg dose 48 complete cytogenetic 48 squamous histology 48 dexmedetomidine 48 euthymic patients 48 pharmacokinetics PK 48 NSTEMI 48 GERD symptom 48 complete remissions 48 International Prostate Symptom 48 antiretroviral naive 48 paricalcitol 48 CANCIDAS 48 nmol L 48 mcg BID 48 fructosamine 48 Kaplan Meier estimates 48 postoperative AF 48 SVR# 48 pegylated interferon alfa 2b 48 heterozygotes 48 randomized controlled trial 48 plasma folate 48 Tasigna prolongs 48 ARB telmisartan 48 PSA nadir 48 autonomic dysfunction 48 HRQL 48 confounder 48 #OHD 48 tumor recurrence 48 weekly subcutaneous injections 48 thromboembolic 48 GnRH agonist 48 FFNS 48 adrenal suppression 48 KRAS status 48 carotid IMT 48 leukocyte count 48 hypoglycaemic episodes 48 trials RCTs 48 MMSE 48 mammographic density 48 demographic variables 48 pravastatin 47 lipid profiles 47 receiving VELCADE 47 completely resected 47 exploratory endpoints 47 moderate renal impairment 47 placebo controlled clinical trials 47 Ki# 47 p ≤ 47 thyrotropin levels 47 FOLFIRI 47 IBDQ 47 sUA 47 CLBP 47 symptomatic intracerebral hemorrhage 47 = #.#-#.# 47 irbesartan 47 dacarbazine chemotherapy 47 dosage regimens 47 pg ml 47 hyperintensities 47 histologies 47 NIH CPSI 47 events TEAEs 47 serum insulin 47 underwent CABG 47 rs# [002] 47 nmol L. 47 intraclass correlation coefficient 47 postoperative mortality 47 PANSS 47 plus methotrexate 47 etanercept 47 MDRD 47 TRITON TIMI 47 plasma uric acid 47 polyp recurrence 47 recurrent VTE 47 PRADAXA #mg 47 serum ferritin 47 circulating IGF 47 mg kg 47 ABCB1 47 intracerebral hemorrhage 47 mL/min/#.# m 2 47 proteinuria 47 SAEs 47 prostate cancer PCa 47 methotrexate monotherapy 47 diastolic BP 47 sham acupuncture 47 seroconversion 47 pretreatment baseline 47 pT2 47 somatostatin analog 47 myocardial infarction MI 47 peginterferon alfa 2b 47 histologically proven 47 MSLT 47 prospective multicentre 47 FDA defined valvulopathy 47 prolactin levels 47 β blocker 47 CLA supplementation 47 receiving ISENTRESS 47 nmol liter 47 elevated liver enzymes 47 Y BOCS 47 evaluable patients 47 Index CDAI 47 RLS symptoms 47 antibody titer 47 undergone radical prostatectomy 47 pramipexole 47 plasma concentrations 47 concordance 47 biopsy Gleason 47 dehydroepiandrosterone sulfate 47 #.#mmHg 47 lymphopenia 47 liver biopsies 47 serum cortisol 47 FDG PET scans 47 ETDRS 47 CHD mortality 47 IELT 47 perfusion abnormalities 47 dietary folate 47 lipid lowering medications 47 neutrophil counts 47 cortical thickness 47 peak VO2 47 flow mediated dilation 47 imatinib therapy 47 Timed Walk 47 hypogonadal 47 normoxic 47 kappa = 47 placebo controlled trials 47 CI = 47 mg/m2 dose 47 HBeAg positive patients 47 % CI #.#-#.# [008] 47 Epidemiologic studies 47 vasomotor symptoms 47 Negative Syndrome 47 mean baseline HbA1c 47 confounding variables 47 inhibin B 47 serum ALT 47 comparator 47 lung metastases 47 primary endpoints 47 randomized controlled 47 salivary cortisol 47 ALT flares 47 Charlson comorbidity index 47 XIENCE V PROMUS Stent 47 aldosterone antagonist 47 ziprasidone 47 EURIDIS 47 Preoperatively 47 fasting plasma 47 Visual Analog Scale 47 serum calcium 47 pg mL 47 thromboembolism 47 femoral neck bone 47 P ≤ 47 nulliparous women 47 statistically significant predictor 47 nondepressed 47 T2 lesions 47 renal dysfunction 47 intermittent dosing 47 spine BMD 47 rimonabant #mg 47 Longitudinal studies 47 alanine aminotransferase ALT 47 pulmonary toxicity 47 POAG 47 pregabalin 47 leukopenia 47 SIDS infants 47 visceral adiposity 47 hormone receptor negative 47 meta analyzes 47 hematological parameters 47 cardio respiratory fitness 47 Kruskal Wallis test 47 protein excretion 47 surrogate markers 47 abacavir 47 intradermal injections 47 underwent resection 47 NATRECOR R 47 glimepiride 47 Hb A1c 47 NYHA 47 tumor regressions 47 EDSS scores 47 Linear regression 47 Observational studies 47 nonvertebral fractures 47 NMIBC 47 μg L 47 IRLS 47 Fasting plasma glucose 47 clinically detectable 47 subclinical cardiovascular disease 47 UPDRS scores 47 retrospective observational study 47 serum creatinine levels 47 infarct size 47 adjunctive ABILIFY 47 efficacy endpoint 47 plasma glucose 47 neurocognitive function 47 hydroxyvitamin D levels 47 urine albumin 47 β = 47 otamixaban 47 Charlson Comorbidity Index 47 inflammatory lesions 47 experienced virologic failure 47 mg BID 47 statistically significant superiority 47 MADRS 47 Symptom severity 47 hippocampal volume 47 sulcal 47 blood Phe 47 varicoceles 47 g dL 47 biochemical abnormalities 47 tolvaptan 47 poorer prognosis 47 BENICAR HCT 47 axillary lymph nodes 47 transferrin saturation 47 cortisol concentrations 47 remission CR 47 amnestic MCI 47 abnormal lipid levels 47 diastolic pressures 47 lymphocytosis 47 Kaplan Meier method 47 virologic 47 HCV genotype 47 binary logistic regression 47 salmeterol HFA MDI 47 achieved CCyR 47 subscores 47 creatine kinase 47 INC# 47 GOUT 47 tolterodine ER 47 pairwise comparisons 47 valsartan 47 serum folate concentrations 47 linear regression analyzes 47 antihypertensive drugs 47 randomization 47 nonfasting 47 colesevelam HCl 47 pamidronate 46 Hazard Ratio HR 46 adjuvant therapies 46 #μg [002] 46 complete cytogenetic response 46 alicaforsen enema 46 nmol l 46 Scale PANSS 46 systolic diastolic 46 socioeconomic status 46 urinary excretion 46 clinical endpoints 46 genotypic 46 QT QTc 46 CORD II 46 #OHD levels 46 Health Assessment Questionnaire 46 prospectively evaluated 46 levosimendan 46 hematological adverse 46 STN stimulation 46 anterior temporal 46 impaired glucose metabolism 46 lowest quartile 46 interquartile range IQR 46 ezetimibe simvastatin 46 eosinophil count 46 APOC3 46 postprocedure 46 hip resurfacing arthroplasty 46 LDL particle 46 serum cotinine levels 46 ECOG PS 46 undergoing coronary angiography 46 graft occlusion 46 glycoprotein IIb IIIa inhibitors 46 glargine 46 nonmetastatic prostate cancer 46 flutamide 46 CIN2 + 46 pre menopausal 46 rotigotine 46 SUVmax 46 perinatal outcomes 46 radiographic progression 46 lamotrigine 46 reinfarction 46 ADHD RS 46 4mg/kg 46 logistic regression 46 residual platelet reactivity 46 Epidemiological studies 46 colesevelam 46 lignan intake 46 thiopurine 46 glomerular filtration rate 46 Pearson correlation coefficients 46 surrogate endpoint 46 pharmacokinetic equivalence 46 liver transaminases 46 candesartan 46 scintigraphic 46 RRM1 46 mg TID 46 plasma adiponectin 46 tenecteplase 46 ischemic lesions 46 Scale EDSS 46 Insulin sensitivity 46 metformin monotherapy 46 cTnI 46 sternal wound infections 46 squamous 46 pharmacodynamic endpoints 46 N telopeptide 46 contralateral 46 prepubertal 46 metabolite concentrations 46 RRMS patients 46 BPS IC 46 nephrotoxicity 46 lymph node metastasis 46 telmisartan 46 ALLHAT 46 serum lipid levels 46 LDL HDL 46 flavonoid intake 46 FluCAM arm 46 pmol L 46 cTnT levels 46 preoperatively 46 HbA 1C 46 vaginal progesterone gel 46 Descriptive statistics 46 lymphadenectomy 46 PCa 46 arterial oxygen saturation 46 Interrater reliability 46 bosentan 46 stage IIIB 46 sinus rhythm 46 iodixanol 46 HBeAg seroconversion 46 Fibromyalgia Impact Questionnaire 46 Non inferiority 46 stage IIIb IV 46 pioglitazone